Media stories about ObsEva SA (NASDAQ:OBSV) have been trending somewhat positive on Thursday, Accern reports. Accern identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ObsEva SA earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned media stories about the company an impact score of 44.7623283797265 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

OBSV has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and set a $27.00 price target on shares of ObsEva SA in a research report on Friday, September 8th. Zacks Investment Research cut ObsEva SA from a “hold” rating to a “sell” rating in a report on Saturday, August 19th. Royal Bank Of Canada assumed coverage on ObsEva SA in a report on Thursday, September 14th. They set an “outperform” rating and a $22.00 price objective for the company. Leerink Swann restated an “outperform” rating and set a $18.00 price objective on shares of ObsEva SA in a report on Wednesday, August 16th. Finally, Credit Suisse Group assumed coverage on ObsEva SA in a report on Monday, October 9th. They set an “outperform” rating and a $16.00 price objective for the company. Six investment analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and an average price target of $18.83.

Shares of ObsEva SA (NASDAQ:OBSV) opened at 9.85 on Thursday. The stock’s 50 day moving average price is $8.00 and its 200-day moving average price is $7.70. ObsEva SA has a one year low of $5.00 and a one year high of $14.69. The company’s market cap is $280.69 million.

ObsEva SA (NASDAQ:OBSV) last issued its quarterly earnings results on Tuesday, August 15th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.13). During the same period in the prior year, the firm posted ($0.30) EPS. On average, analysts expect that ObsEva SA will post ($2.46) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This article was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at

About ObsEva SA

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.

Insider Buying and Selling by Quarter for ObsEva SA (NASDAQ:OBSV)

Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with Analyst Ratings Network's FREE daily email newsletter.